transcription factor; kidney-specific gene regulation; mouse inner medullary collecting duct-3 cells; deoxyribonuclease hypersensitive sites; maturity-onset diabetes of the young KIDNEY-SPECIFIC CADHERIN (Ksp-cadherin or cadherin 16) is a unique, tissue-specific member of the cadherin family of cell adhesion proteins. Cadherins are plasma membrane glycoproteins that mediate calcium-dependent, homotypic cell-cell interactions and play important roles in morphogenesis, cell migration, cell differentiation, and signal transduction (2, 37) . Ksp-cadherin is a structurally distinct member of the family that has a highly restricted tissue distribution. In the adult rabbit, mouse, and human, Ksp-cadherin is expressed exclusively in the kidney (30, 31) . Within the kidney, Ksp-cadherin is restricted to renal tubules and is not expressed in glomeruli, blood vessels, or interstitial cells. The protein is located in the basolateral membrane of epithelial cells in all segments of the nephron, including proximal tubules, loops of Henle, distal tubules, and renal collecting ducts (29) . During embryonic development, Ksp-cadherin is expressed in the developing kidney and genitourinary (GU) tract (29, 33) . In the embryonic kidney (metanephros), Ksp-cadherin is expressed in developing renal tubules beginning after the S-shaped body stage and in the branching ureteric bud, which is the anlage of the renal collecting ducts, pelvis, and ureter. Ksp-cadherin mRNA transcripts have also been detected in mesonephric tubules and in the two paired sex ducts, the Wolffian (mesonephric) duct and the Mü llerian (paramesonephric) duct. However, the expression in the developing GU tract is transient, since there is no expression in the adult renal pelvis, ureter, or male and female genital tracts.
To explore the mechanism of tissue-specific and developmentally regulated expression of Ksp-cadherin, our laboratory previously cloned and characterized the gene promoter (34) . The proximal 2,608 bp of the Kspcadherin promoter direct expression of a luciferase reporter gene in transfected renal epithelial cells but not in mesenchymal cells (34) . Deletion analysis has shown that truncation of the promoter from Ϫ2,608 to Ϫ250 bp does not significantly decrease promoter activity in renal epithelial cells. However, further truncation to Ϫ113 bp reduces promoter activity by 40%, and truncation to Ϫ31 bp completely abolishes activity. Transgenic mice containing 3.3 kb of the Ksp-cadherin promoter linked to a lacZ reporter gene express ␤-galactosidase exclusively in the ureteric bud and renal collecting ducts, verifying that the activity of the promoter is tissue specific in vivo (15) . Recent studies have shown that 1,268 bp of the promoter recapitulate the complete expression pattern of the endogenous Kspcadherin gene in the kidney and developing GU tract, and the proximal 250 bp of the promoter are sufficient for tissue-specific expression (28) . This region of the promoter contains potential recognition sites for the transcription factor hepatocyte nuclear factor (HNF-1).
HNF-1 consists of two proteins, HNF-1␣ and HNF-1␤, that have been implicated in tissue-specific gene regulation in the liver, pancreas, kidney, and intestine (16, 20, 27) . HNF-1␣ and HNF-1␤ contain an atypical homeodomain, an NH 2 -terminal dimerization domain, and a POU domain. They bind to DNA as homodimers or heterodimers and recognize an identical consensus sequence (19) . HNF-1␣ is a transcriptional activator and contains three distinct activation domains within its COOH terminus. This domain is not conserved in HNF-1␤, which has been reported to function as an activator or a repressor or to have no transcriptional activity, depending on the promoter and cell type (20, 27) . Both HNF-1␣ and HNF-1␤ are highly expressed in the developing kidney but in different patterns. HNF-1␣ is primarily expressed in proximal tubules, whereas HNF-1␤ is expressed in all nephron segments and the renal collecting system and sex ducts. The current study was undertaken to investigate whether HNF-1␣ and/or HNF-1␤ regulate the Ksp-cadherin gene promoter. We show that both proteins can bind specifically to the promoter and directly stimulate its activity. In addition, the activity of the Ksp-cadherin promoter is altered by the expression of HNF-1␤ mutants that are similar to those found in humans with inherited renal cysts and diabetes.
MATERIALS AND METHODS

Materials.
Restriction endonucleases and DNA-modifying enzymes were from New England Biolabs (Beverly, MA) or Roche Molecular Biochemicals (Indianapolis, IN). pGL3 plasmids, pSV2␤gal, luciferin, and reporter lysis buffer were from Promega (Madison, WI). Galacton-Star ␤-galactosidase substrate was obtained from Tropix (Bedford, MA). Plasmid prep kits and Effectene transfection reagent were from Qiagen (Valencia, CA). Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA) and were purified by polyacrylamide gel electrophoresis. The QuikChange site-directed mutagenesis system was from Stratagene (La Jolla, CA). Antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Tissue culture media were from Life Technologies (Gaithersburg, MD). Other reagents were of molecular biological grade from Sigma (St. Louis, MO), Promega, or Roche Molecular Biochemicals.
Animals. HNF-1␣-deficient mice were produced by replacing the first exon with a LacZ cassette, as described previously (24) . Studies were performed using 2-to 3-wk-old HNF-1␣ (Ϫ/Ϫ) mice and their age-matched heterozygous HNF-1␣ (ϩ/Ϫ) and wild-type HNF-1␣ (ϩ/ϩ) littermates. Mice were genotyped by PCR analysis of tail DNA, as described previously (24) . The genetic background of the animals was either C57BL/6 ϫ 129/Sv or 129Sv/DBA2/C57BL/6.
Plasmids. A plasmid (pBS-KS-HNF1␣) containing the mouse HNF-1␣ cDNA and a plasmid (pBJ5-HNF1␤) containing the mouse HNF-1␤ cDNA (B splice variant) were generous gifts from Dr. Gerald Crabtree (Stanford University). The 3.1-kb EcoRI fragment from pBJ5-HNF1␤ was cloned into the EcoRI site of pBluescript II KS(ϩ), creating the plasmid pBS-KS-HNF1␤. The HNF-1␣ coding region was amplified from pBS-KS-HNF1␣ with primers 5Ј-ACCATGGTTTCT-AAGCTGAGCCAGCTG and 5Ј-GGGTTTAAACTTACTGG-GAAGAGGAGGCCATCTGG and cloned into pcDNA3.1/V5/ His-TOPO (Invitrogen), creating the expression plasmid pcDNA3-HNF1␣. The HNF-1␤ coding region was amplified from pBS-KS-HNF1␤ with primers 5Ј-ACCATGGTGTC-CAAGCTCACGTCGCTC and 5Ј-CGGGTTTAAACTCACCA-GGCTTGCAGTGGACACTGT and cloned into pcDNA3.1/V5/ His-TOPO, creating the expression plasmid pcDNA3-HNF1␤. The coding regions of both plasmids were sequenced completely.
An expression plasmid encoding a truncated form of mouse HNF-1␤ lacking 236 amino acids at the COOH terminus (pcDNA3-HNF1␤⌬C) was produced by PCR amplification from pBS-KS-HNF1␤ using primers 5Ј-ACCATGGTGTC-CAAGCTCACGTCGCTC and 5Ј-CTGGTTGGAGCTATAG-GCATCCAT and cloning into pcDNA3.1/V5/His-TOPO. A stop codon was introduced between the V5 and His epitope tags by PCR amplification with primers 5Ј-GTTTAAA-CGATATCGTTAACGCGTAGAATCGAGACCGAGGAG and 5Ј-ACCATGGTGTCCAAGCTCACGTCGCTC. The PCR product was digested with EcoRV, and the 100-bp fragment was cloned into the EcoRV site of the plasmid. An expression plasmid encoding a mutant form of mouse HNF-1␤ corresponding to the human A263fsinsGG mutation (pcDNA3-A263fsinsGG) was produced by PCR amplification using primers 5Ј-ACCATGGTGTCCAAGCTCACGTCGCTC and 5Ј-CTAACCGGCCTCCCTCTCTTCCTTGC and cloning into pcDNA3.1/V5/His-TOPO.
A reporter plasmid containing the proximal Ksp-cadherin promoter was derived from pKsp(2608F)-Luc (34) by digestion with AvrII and NheI, removal of the 924-and 1,571-bp fragments, and recircularization. The resulting plasmid [pKsp(113)-Luc] contained nucleotides Ϫ113 to ϩ74 of the Ksp-cadherin promoter linked to a luciferase reporter gene.
Site-directed mutagenesis. Site-directed mutagenesis was performed using QuikChange kits (Stratagene) according to the manufacturer's directions. Complementary sense and antisense oligonucleotides containing the desired mutations (Table 1) were synthesized and purified by PAGE. The mutagenic primers were annealed to the luciferase reporter plasmid and extended using PfuTurbo DNA polymerase. Eighteen cycles of denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and elongation at 68°C for 10 min were performed. The parental DNA template was then digested with DpnI, and the mutated plasmids were transformed into Escherichia coli. The presence of the desired mutation was verified by DNA sequencing. DNA for transfections was purified by alkaline lysis maxipreps and anion-exchange chromatography (Qiagen). Mutant reporter plasmids were produced containing the mutations listed in Table 1 , except mutation 6.
Cell culture and transfection. Mouse inner medullary collecting duct cells (mIMCD-3) were a generous gift from Dr. Stephen Gullans (Harvard Medical School) and were grown in DMEM supplemented with 10% FBS (26) . HeLa cells were obtained from American Type Culture Collection (Manassas, VA) and were maintained in Iscove's modified Dulbecco's media supplemented with 2% FBS and 5% newborn calf serum. C3H/10T1/2 cells were obtained from ATCC and were maintained in basal Eagle medium supplemented with 10% FBS.
Plasmids were transiently transfected in cultured cells using Effectene (Qiagen). Cells were plated in six-well dishes at a density of 1.2-3 ϫ 10 5 cells/well. After overnight growth to ϳ60% confluence, the cells were washed one time with PBS and then transfected with 0.6-3 g plasmid. Plasmid DNA and enhancer (2 times the amount of DNA, vol/wt) were combined in 100 l of buffer and incubated for 2-5 min. Effectene reagent (10 l) was added, and the mixture was incubated for 5-10 min at room temperature to permit complex formation. Growth medium (0.6 ml) was added, and the mixture was added drop-wise on the cells. In each experiment, the total amount of transfected DNA was maintained constant by the addition of empty expression plasmid. To control for differences in transfection efficiency, cells were cotransfected with a constant amount of plasmid pSV2-␤Gal or pCMV-␤Gal encoding E. coli ␤-galactosidase. Transfected cells were grown in standard culture medium for 48 h and then were assayed for luciferase and ␤-galactosidase activity.
Reporter gene assays. Luciferase activity was measured in cell lysates using methods similar to those described previously (34) . Cells were washed with PBS and then lysed by incubation for 20 min at room temperature in 150 l Reporter Lysis Buffer (Promega). Lysates were frozen one time at Ϫ70°C, thawed, and then centrifuged at 14,000 g. Supernatant (20 l) was added to 100 l of Luciferase Assay Reagent (Promega). After a 1-s delay, light output was measured for 10 s using an Optocomp I luminometer (MGM Instruments, Hamden, CT). Luciferase activity was normalized to ␤-galactosidase activity, which was measured by adding 20 l of cell lysate to 300 l of reaction buffer containing Galacton-Star (Tropix), 100 mM sodium phosphate (pH 7.5), 1 mM MgCl 2, and 5% Sapphire-II (Tropix). After incubation for 60 min at room temperature, light output was measured for 5 s using a luminometer. In some experiments (see Fig. 7C ) in which the expression of HNF-1␤ mutants affected ␤-galactosidase activity, luciferase activity was normalized to protein concentration. Protein concentration was measured using the Pierce Coomassie Plus Protein Assay (Rockford, IL) with BSA as the standard.
In vitro translation. In vitro translation was performed using TNT Quick-coupled transcription/translation kits (Promega) according to the manufacturer's directions. pBluescript plasmid (1 g) containing the full-length cDNAs encoding HNF-1␣ or HNF-1␤ (pBS-KS-HNF1␣ and pBS-KS-HNF1␤, respectively) was added to TNT Quick master mix in a total volume of 50 l. Transcription was performed using T7 RNA polymerase, and translation was performed using rabbit reticulocyte lysates. Reactions were incubated at 30°C for 60-90 min, and 5 l of the reaction product were used for electrophoretic mobility shift assays (EMSA). Unprogrammed lysates were used as negative controls.
Preparation of nuclear extracts from cultured cells. Nuclear extracts were prepared from mIMCD-3 cells using the method of Andrews and Faller (1) . Confluent cells were grown in 100-mm dishes (ϳ5 ϫ 10 6 cells) and then were scraped into 1.5 ml PBS and pelleted. Cells were lysed by incubation for 15 min in ice-cold medium containing 10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl 2, 10 mM KCl, 0.5 mM dithiothreitol (DTT), and 0.2 mM phenylmethylsulfonyl fluoride (PMSF). Nuclei were pelleted by centrifugation and then extracted for 20 min at 4°C with 20 mM HEPES-KOH (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM PMSF. After centrifugation for 45 min at 14,000 g, the supernatant was diluted 1:1 with buffer containing 5 mM HEPES-KOH (pH 7.9), 20% glycerol, 1 mM DTT, and 0.2 mM PMSF and was stored at Ϫ70°C.
EMSA. EMSA were performed as described previously (34) . Double-stranded oligonucleotides containing the sequences of the promoter from Ϫ46 to Ϫ13 bp (5Ј-CTAGGC-GGGGCCACGGCTGCTCCTGTGGGCCCCG) or from Ϫ79 to Ϫ50 bp (5Ј-GGCTCTCCAAAGTCAATAAGTAACTTGGGG) were end labeled with 32 P using T4 polynucleotide kinase. Binding reactions (20 l) contained 25 mM NaCl, 10 mM Tris ⅐ Cl (pH 7.5), 1 mM MgCl 2, 5 mM EDTA, 5% glycerol, 1 mM DTT, 1 ϫ 10 6 counts/min labeled probe, and 2-4 g nuclear extracts or 5 l programmed lysates. In some reactions, a 5-to 100-fold molar excess of unlabeled oligonucleotide was included as a specific competitor. All binding reactions contained 200 ng poly(dI ⅐ dC) or poly(dA ⅐ dC) as nonspecific competitor. After incubation at 4°C or room temperature for 20 min, samples were loaded on 4% polyacrylamide gels and electrophoresed at 8 V/cm for 2 h in 0.5ϫ Tris-borate-EDTA. Gels were dried, and the radiolabeled bands were detected by autoradiography using Kodak BioMax MS film.
Northern blot analysis. Total RNA was isolated from the kidneys of HNF-1␣ mutant homozygous, heterozygous, and wild-type mice and subjected to Northern blot analysis as described previously (24, 25) . Northern blots were hybridized with a 700-bp mouse Ksp-cadherin cDNA and an 11␤-hydroxysteroid dehydrogenase type 1 cDNA as a control. Auto- Table 1 . Sequences of mutations used in this study GC-box GC-box
Boxes indicate the consensus hepatocyte nuclear factor (HNF)-1 site, HNF-3 site, and GC boxes. (The HNF-1 site shown is the reverse complement of the consensus.) Underlined nucleotides indicate mutations. Nucleotide positions are numbered relative to the transcription start site at ϩ1. radiography and quantification of band intensities were performed using a PhosphorImager.
DNase I hypersensitive site mapping. DNase I hypersensitive site mapping was performed according to Boyes and Felsenfeld (7) . mIMCD-3 or 10T1/2 cells (1 ϫ 10 8 cells) were trypsinized, washed two times in PBS, and then resuspended in 1 ml of 0.34 M sucrose, 10 mM HEPES (pH 8.0), 60 mM KCl, 2 mM EDTA, 1.5 mM DTT, 0.5 mM spermine, and 0.15 mM spermidine (buffer A) containing 0.5% IGEPAL CA-630. All buffers were ice-cold unless otherwise indicated. Nuclei were immediately pelleted at 2,060 g for 5 min at 4°C and then washed one time in 5 ml buffer A without IGEPAL CA-630. Nuclei were resuspended in 1 ml of 10 mM HEPES (pH 8.0), 20 mM KCl, 3 mM MgCl 2, and 6 mM CaCl2 (buffer B), and 100-l aliquots (1 ϫ 10 7 nuclei) were added to tubes containing increasing concentrations of DNase I (Sigma) diluted in 100 l buffer B. The concentrations of DNase I ranged from 0.2 to 10 g, and one sample was kept as a no DNase I control. Nuclei containing DNase I were placed in a 37°C water bath for 5 min, and then the reaction was stopped by adding 200 l of 0.1 M Tris (pH 7.5), 20 mM EDTA, 1% SDS, and 0.5 M NaCl (buffer C). Buffer C was also added to the no DNase I control. Samples were treated with RNase A for 1 h at 37°C and then digested with 10 g proteinase K overnight at 55°C. Genomic DNA was purified by phenol/ chloroform extraction and ethanol precipitation. DNase I "fadeout" was confirmed by agarose gel electrophoresis and staining with ethidium bromide. DNA (10 g) was digested with HindIII, electrophoresed on a 0.8% agarose gel, transferred to a nylon membrane, and hybridized with 5Ј-or 3Ј-probes near the HindIII sites. The probes used were a 443-bp HindIII/StuI restriction fragment containing nucleotides Ϫ1,265 to Ϫ822 bp (5Ј-probe) and a 713-bp fragment containing nucleotides ϩ2,005 to ϩ2,718 bp (3Ј-probe) that was generated by PCR with primers 5Ј-CCTATCAG-GAGACTCAAACACGGC and 5Ј-AATGTGGAAGCGAAG-GTCGG. PCR reaction conditions were 40 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min using genomic DNA from mIMCD-3 cells as the template.
Statistical analysis. Results of reporter gene assays are expressed as the means Ϯ SE of three to nine independent transfections assayed in duplicate. The statistical significance of differences between the means was evaluated using Student's t-test or one-way ANOVA as appropriate. Scheffé's test was used for post hoc comparisons. Differences were considered to be significant at P Ͻ 0.05.
RESULTS
The proximal Ksp-cadherin gene promoter is evolutionarily conserved between mouse and human. The DNA elements that are essential for regulation of gene expression are often conserved between different species. To identify evolutionarily conserved regions within the Ksp-cadherin gene promoter, the sequence of the mouse promoter was compared with the sequence of the human genome in the NCBI database. A BLASTN search was performed using 1,268 bp of the mouse promoter, since this region is sufficient to recapitulate the complete expression pattern of the gene in transgenic mice (28) . A draft (phase 1) sequence of the human Ksp-cadherin gene was identified in the High Throughput Genomic Sequences database (accession no. AC009084). The human sequence was contained within a 222-kb bacterial artificial chromosome (BAC) derived from chromosome 16, which was consistent with the chromosomal localization of the Ksp-cadherin gene (CDH16), as previously determined by fluorescence in situ hybridization (31) . An alignment of the sequence of the BAC with the sequence of the human Ksp-cadherin cDNA revealed that the BAC contained the entire Ksp-cadherin gene on a single 56-kb contig. The gene consisted of 18 exons distributed over 10.7 kb (Fig. 1A) . All of the exon-intron boundaries conformed to the GT/AG rule (data not shown). The contig also contained 39 kb of sequence 5Ј to the human Kspcadherin gene, which included the gene promoter. The sequence of the human promoter was independently verified using adapter-ligation PCR and was 98% identical to the sequence derived from the BAC (data not shown). Figure 1B shows the alignment of the proximal promoters of the mouse and human Ksp-cadherin genes, and Fig. 1C shows a plot of the percent identity over the region. Overall, the mouse and human promoters were 62% identical (excluding gaps). However, two regions were Ͼ80% identical: a 38-bp sequence beginning at nucleotide Ϫ762 containing three to four tandem repeats (data not shown) and the 120-bp region immediately upstream of the transcription start site. The proximal 120 bp of the promoter were even more highly conserved than the 5Ј-untranslated region of the mRNA transcript. The consensus binding site for HNF-1 at nucleotide Ϫ55, the consensus HNF-3 site at nucleotide Ϫ62, and the GC-rich region from nucleotides Ϫ15 to Ϫ43 were highly conserved in the mouse and human promoters, highlighting the potential importance of these elements for promoter activity.
The proximal Ksp-cadherin promoter contains a DNase I hypersensitive site that is cell type specific. The binding of transcription factors to specific sites in DNA is accompanied by local disruptions of chromatin that render DNA in the region more susceptible to digestion by exogenous nucleases (13) . Sites that are relatively sensitive to digestion by deoxyribonuclease (so-called DNase hypersensitive sites), particularly those that are cell type specific, represent potential binding sites for transcription factors involved in tissue-specific expression. To identify DNase hypersensitive sites in the Ksp-cadherin gene, nuclei were harvested from mIMCD-3 renal epithelial cells, which express endogenous Ksp-cadherin, and were incubated with graded concentrations of DNase I. Genomic DNA was then isolated, and a 4.2-kb HindIII restriction fragment containing the first six exons of the gene and 1.3 kb of the 5Ј-flanking region was visualized by indirect end labeling. Figure 2A shows the genomic structure of the 4.2-kb fragment and the 3Ј-probe that was used for indirect end labeling. Figure 2B shows that incubation with increasing concentrations of DNase I resulted in gradual disappearance of the 4.2-kb parental band and the appearance of a 3-kb subband. The size of the subband corresponded to a DNase I hypersensitive site located ϳ100 bp 5Ј to the transcription initiation site. The position of the hypersensitive site was confirmed by hybridization to a 5Ј-probe (data not shown). No additional sites were observed within the 1.3-kb region of the 5Ј-flanking sequence. As a negative control, nuclei were harvested from 10T1/2 cells, which do not express Ksp-cadherin, and were treated identically. Figure 2C shows that incubation with increasing concentrations of DNase I resulted in gradual disappearance of the parental band but no appearance of a subband. These results demonstrate that the proximal 100 bp of the Ksp-cadherin promoter contain a DNase I hypersensitive site that is cell type specific, the appearance of which correlates with gene transcription.
Mutations of the consensus HNF-1 site and GC-rich region inhibit Ksp-cadherin promoter activity in mIMCD-3 cells. Previous analysis of the Ksp-cadherin promoter indicated that the 82-bp region of the promoter from nucleotides Ϫ113 to Ϫ31 was essential for promoter activity in transfected renal epithelial cells and that mutations of the region from nucleotides Ϫ60 to Ϫ71 produced varying degrees of inhibition of promoter activity (34) . To confirm and extend these results, we performed additional mutational analysis of the proximal promoter. A series of 3-bp transversion mutations were introduced into the minimal Ksp-cadherin promoter downstream of the four mutations (m1-m4) characterized previously (Table 1) . Mutation 13 disrupted highly conserved nucleotides in the putative HNF-1 site at nucleotide Ϫ55, and mutations 5-10 disrupted the GC-rich region extending from nucleotides Ϫ15 to Ϫ43. Luciferase reporter plasmids containing the mutant and wild-type promoter sequences were transiently transfected into mIMCD-3 cells, and luciferase activity was measured 48 h later (Fig. 3A) . As previously shown, mutations 2-4, which disrupted both the consensus HNF-1 site and the overlapping HNF-3 site, inhibited promoter activity by 70-80%. Mutation 1, which disrupted the consensus HNF-3 site, but not the HNF-1 site, produced only a slight inhibition that was not statistically significant. Mutation 13, which disrupted only the consensus HNF-1 site, inhibited promoter activity by 80%. Mutations of the downstream GC-rich region (m5, m7, m8, and m9) also inhibited promoter activity, although mutation 10 had no significant effect. These results indicated that mutations of the consensus HNF-1 binding site and some of the GC boxes inhibited Ksp-cadherin promoter activity in transfected renal epithelial cells. Figure 3B compares the effects of mutations of the Ksp-cadherin promoter in transfected mIMCD-3 cells, which express endogenous HNF-1, and HeLa cells that do not contain HNF-1. Transfection of the wild-type promoter-reporter plasmid in mIMCD-3 cells produced high levels of luciferase activity, and mutations of the consensus HNF-1 binding site (m3 and m13) inhibited activity by 75-80% (filled bars). In contrast, the wildtype Ksp-cadherin promoter had low activity in HeLa cells, and mutations 3 and 13 had no significant effect (open bars). These results indicated that the effects of the mutations were specific.
HNF-1␣ and HNF-1␤ bind specifically to the Kspcadherin promoter. The mouse Ksp-cadherin gene promoter contained a consensus HNF-1 binding site at nucleotide position Ϫ55 of the noncoding strand. The sequence of the promoter (5Ј-AGTTACTTATTGACT-3Ј) matched the consensus sequence (5Ј-RGTTAAT-NATTAACM-3Ј) (19) at 12 of 15 positions and was identical at 9 positions that are highly conserved in known HNF-1 sites (underlined). The sequences of the mouse and human promoters were identical in this region except for a single nucleotide substitution at a redundant position (N). The putative HNF-1 binding site overlapped with the HNF-3 site at nucleotide Ϫ62 and was contained within the 82-bp region that had previously been shown to be important for promoter activity in transfected renal epithelial cells. Moreover, mutations of the sequence that altered highly conserved nucleotides (m3 and m13) inhibited promoter activity in mIMCD-3 cells by 80% (Fig. 3) .
To determine whether HNF-1␣ and/or HNF-1␤ could bind to the Ϫ55 site of the Ksp-cadherin promoter, EMSA was performed using programmed reticulocyte lysates and a radiolabeled oligonucleotide containing the Ϫ55 site. Figure 4A shows that binding activity was present in lysates programmed with HNF-1␣ (lane 3) or HNF-1␤ (lane 9) but was not present in unprogrammed lysates (lane 2). Binding was specific since it could be competed with increasing concentrations of unlabeled wild-type oligonucleotide (lanes 4, 6, 10, and 12) but not with equivalent amounts of an oligonucleotide containing a mutation (m3) of the consensus HNF-1 site (lanes 5, 7, 11, and 13). A consensus HNF-1 binding site from the ␤-fibrinogen promoter also competed for binding, although less effectively than the wild-type sequence (lanes 8 and 14) .
Northern blot analysis showed that mIMCD-3 cells endogenously expressed HNF-1␤ but did not express HNF-1␣, consistent with the pattern of expression of these genes in the renal collecting duct from which this cell line was derived (data not shown). To determine whether mIMCD-3 cells contained endogenous HNF-1␤ that bound to the Ϫ55 site, EMSA was performed using nuclear extracts. Figure 4B , lanes 2 and 6, shows that nuclear extracts from mIMCD-3 cells contained proteins that bound to an oligonucleotide containing the Ϫ55 site in a concentration-dependent manner. Binding was specific, since it could be competed with a 100-fold excess of unlabeled oligonucleotide (lane 10). To verify the presence of HNF-1␤ in the DNA-protein complex, binding was performed in the presence of specific antibodies against HNF-1␣ or HNF-1␤. Addition of an antibody against HNF-1␤ resulted in a supershift, indicating that HNF-1␤ was present in the DNA-protein complex (lanes  4 and 8) . In contrast, no supershift was observed after addition of an equal amount of irrelevant antibody (lanes 5 and 9). Moreover, no supershift was observed after addition of an antibody directed against HNF-1␣ (lanes 3 and 7), consistent with the absence of HNF-1␣ in mIMCD-3 cells. Control experiments verified that the HNF-1␣ antibody could supershift the complex formed by HNF-1␣ in programmed reticulocyte lysates (data not shown).
To determine whether an independent mutation of the consensus HNF-1 site also disrupted protein binding, we studied the effects of mutation 13 (Table 1) . Competitive EMSA was performed using lysates programmed with HNF-1␣ or HNF-1␤ (Fig. 4C) or nuclear extracts from mIMCD-3 cells (Fig. 4D) . In each case, there was specific binding to an oligonucleotide containing the Ϫ55 site, which could be competed with excess unlabeled wild-type oligonucleotide. However, like mutation 3, an excess of unlabeled oligonucleotide containing mutation 13 was unable to compete, indicating that mutation 13 disrupted the HNF-1 binding site. Taken together, these results demonstrate that disruption of conserved nucleotides within the consensus recognition site prevented HNF-1 binding.
HNF-1␣ and HNF-1␤ transactivate the Ksp-cadherin promoter directly. To test whether HNF-1␣ or HNF-1␤ could transactivate the Ksp-cadherin promoter, reporter gene assays were performed in transiently transfected HeLa cells, which do not express endogenous HNF-1. HeLa cells were cotransfected with expression plasmids encoding HNF-1␣ or HNF-1␤ and a luciferase reporter plasmid containing the Ksp-cadherin promoter. Figure  5A shows that expression of HNF-1␣ stimulated luciferase activity by 11-fold (open bars), whereas expression of HNF-1␤ produced a 3-fold stimulation (filled bars). HNF-1␣ has previously been shown to be a stronger transcriptional activator than HNF-1␤. At higher concentrations of expression plasmid, luciferase activity began to decrease, consistent with the phenomenon of squelching. Expression of HNF-1␣ together with HNF-1␤ resulted in stimulation of activity that was comparable to HNF-1␣ by itself (data not shown).
To distinguish whether activation of the Ksp-cadherin promoter by HNF-1 was direct or indirect, HeLa cells were cotransfected with HNF-1 expression plasmids and a mutated reporter plasmid containing the same mutation of the Ϫ55 site (m3) that inhibited HNF-1 binding. Figure 5B shows that cotransfection of HNF-1␤ and the wild-type promoter resulted in a twoto threefold stimulation of luciferase activity (open bars), whereas cotransfection of HNF-1␣ and the wildtype promoter resulted in a six-to eightfold stimulation (filled bars), similar to the results shown in Fig.  5A . The stimulation of luciferase activity by HNF-1␣ and HNF-1␤ was completely abolished by cotransfection of a reporter plasmid containing the mutated promoter (gray and hatched bars). These results establish that both HNF-1␣ and HNF-1␤ can stimulate the Kspcadherin promoter and that an intact HNF-1 binding site at position Ϫ55 is required for transactivation.
To extend these results, additional mutational analysis was performed. Figure 5C shows the results of cotransfection of HeLa cells with wild-type or mutant reporter plasmids and an HNF-1␣ expression plasmid (filled bars) or an equivalent amount of empty pcDNA3.1 (open bars). The mutations had no significant effect on the basal promoter activity in HeLa cells (open bars). However, mutations 2, 3, and 13 strongly inhibited or abolished transactivation by HNF-1␣. These mutations disrupted highly conserved nucleotides in the consensus HNF-1 binding site. In contrast, mutations 1 and 7, which do not alter the consensus HNF-1 site, had no significant effect on transactiva- Fig. 3 . Mutational analysis of the Ksp-cadherin promoter. A: luciferase reporter plasmids (0.6 g) containing the wild-type (wt) or mutated (m1-m13) Ksp-cadherin promoter (nucleotides Ϫ113 to ϩ74) were transiently transfected into mIMCD-3 cells, and luciferase activity was measured after 48 h. To control for transfection efficiency, cells were cotransfected with 10 ng pCMV-␤Gal, and luciferase activity was normalized to ␤-galactosidase activity. Data are means Ϯ SE of 9 independent transfections. The mutations that were used are listed in Table 1 . *P Ͻ 0.05 compared with wild-type promoter. B: luciferase reporter plasmids (0.6 g) containing the wild-type or mutated Ksp-cadherin promoter were transiently transfected into mIMCD-3 cells (filled) or HeLa cells (open bars). Cells were cotransfected with 5 ng pCMV-␤Gal, and luciferase activity was normalized to ␤-galactosidase activity. Data are means Ϯ SE of 6 independent transfections. *P Ͻ 0.05 compared with wild-type promoter. tion. Mutation 4, which affects a sequence that is not as highly conserved, produced an intermediate effect.
Expression of Ksp-cadherin in HNF-1␣ mutant mice. Transgenic mice in which the HNF-1␣ (Tcf1) gene has been disrupted by homologous recombination exhibit renal abnormalities and decreased insulin secretion. The renal abnormalities, which include glycosuria, amino aciduria, and phosphaturia, resemble human Fanconi syndrome (24) . The expression of the renal Na ϩ /glucose cotransporter is inhibited in the kidneys from homozygous mutant mice and may be the mechanism for renal glycosuria (25) . To examine the expression of Ksp-cadherin in the kidneys of HNF-1␣ mutant mice, Northern blot analysis was performed. As shown in Fig. 6 , the expression of Ksp-cadherin mRNA normalized to the expression of 11␤-hydroxysteroid dehydrogenase type 1 was similar in HNF-1␣ mutant homozygotes, heterozygotes, and wild-type mice. These results indicated that HNF-1␣ was not essential for the expression of the Ksp-cadherin gene in vivo. to the Ksp-cadherin promoter. A: electrophoretic mobility shift assay (EMSA) was performed using a radiolabeled oligonucleotide containing nucleotides Ϫ79 to Ϫ50 of the Ksp-cadherin promoter and reticulocyte lysates programmed with HNF-1␣ (lanes 3-8) 8 and 14) , or no competitor (Comp) (lanes 3 and 9) . B: EMSA was performed using the Ϫ79/Ϫ50 oligonucleotide and nuclear extracts from Mutations of HNF-1␤ alter the activity of the Kspcadherin promoter. Because HNF-1␤ homozygous null mutations are embryonically lethal before the time of kidney organogenesis (3, 10), it was not possible to examine Ksp-cadherin gene expression in HNF-1␤ mutant mice. As an alternative approach, we examined the effect of mutations of HNF-1␤ on transactivation of the Ksp-cadherin promoter. The P328L329fsins-CCTCT mutation of the human HNF-1␤ gene produces a dominant gain-of-function mutant that contains an intact DNA-binding domain, a deletion of 230 amino acids from the COOH terminus, and a replacement with 29 amino acids from the frame-shifted open reading frame (5, 35) . To test the effects of a similar mutation of mouse HNF-1␤ on Ksp-cadherin promoter activity, mIMCD-3 cells were cotransfected with expression plasmids encoding either wild-type HNF-1␤ or an HNF-1␤ mutant containing a COOH-terminal deletion similar to the one in the human P328L329-fsinsCCTCT mutant (HNF-1␤⌬C). Figure 7A shows that expression of wild-type HNF-1␤ had no effect on promoter activity, presumably because the cells endogenously express HNF-1␤. In contrast, transfection with the COOH-terminal deletion mutant produced a concentration-dependent stimulation of promoter activity, consistent with a gain-of-function mutation. . Cells were also transfected with 5 ng pCMV-␤Gal, and luciferase activity was normalized to ␤-galactosidase activity. Data are means Ϯ SE of 9 independent transfections. *P Ͻ 0.002 compared with wild-type promoter. C: effects of mutations of the Kspcadherin promoter on transactivation by HNF-1␣. HeLa cells were cotransfected with 0.1 g pcDNA3-HNF1␣ (filled bars) or empty pcDNA3 (open bars) and 0.6 g luciferase reporter plasmid containing the wild-type or mutated (m1-m7) Ksp-cadherin promoter. Cells were also transfected with 10 ng pCMV-␤Gal, and luciferase activity was normalized to ␤-galactosidase activity. Data are means Ϯ SE of 3 independent transfections. *P Ͻ 0.05 compared with wild-type promoter. Next, we tested the effect of a dominant-negative mutation of HNF-1␤ on Ksp-cadherin promoter activity. The A263fsinsGG mutation of the human HNF-1␤ gene produces a protein that can dimerize with wildtype HNF-1␤ but is unable to bind DNA and therefore functions as a dominant-negative mutant (32) . Figure  7B shows that a mouse A263fsinsGG mutant inhibited the activity of the Ksp-cadherin promoter by 40% when transfected in mIMCD-3 cells that endogenously express wild-type HNF-1␤. The A263fsinsGG mutant had no significant effect on the activity of the promoter containing mutations of the HNF-1 binding site (m3 and m13), indicating that the inhibition was specific. Figure 7C shows the results of coexpression of HNF-1␤ and the A263fsinsGG dominant-negative mutant in HeLa cells. Expression of wild-type HNF-1␤ by itself stimulated promoter activity fourfold, whereas coexpression of the A263fsinsGG mutant inhibited activation by 60%, consistent with a dominant-negative mutation. Taken together, these results support the role of endogenous HNF-1␤ in Ksp-cadherin promoter activity.
DISCUSSION
HNF-1␣ and HNF-1␤ were first identified in the liver, where they regulate the promoters of liver-specific genes such as albumin and ␣ 1 -antitrypsin (11) . However, HNF-1␣ and HNF-1␤ are also highly expressed in other epithelial tissues, including the kidney (6) . The expression of HNF-1␣ and HNF-1␤ in the kidney overlaps with the expression of Ksp-cadherin. Like Ksp-cadherin, HNF-1␣ and HNF-1␤ are expressed exclusively in tubular epithelial cells in the kidney and are not expressed in glomeruli or in nonepithelial cells. HNF-1␤ is expressed in all segments of the nephron and in renal collecting tubules, whereas HNF-1␣ is primarily expressed in proximal tubules (12, 24) . HNF-1␤ is also expressed in the ureteric bud, mesonephric (Wolffian) duct, and Mü llerian duct, which are all sites of Ksp-cadherin gene expression in the developing embryo (9) . During kidney development, HNF-1␣ and HNF-1␤ are expressed before Kspcadherin (3, 17, 22) . HNF-1␤ appears at embryonic day 12.5 and is expressed in the branching ureteric bud, comma-shaped bodies, S-shaped bodies, and develop- ing renal tubules. HNF-1␣ appears at embryonic day 14.5 and is expressed in late S-shaped bodies and maturing proximal tubules. Thus the patterns of expression, particularly of HNF-1␤, are consistent with a role in regulating Ksp-cadherin gene expression.
Previous studies identified an 82-bp region within the Ksp-cadherin promoter that is essential for activity in transfected renal epithelial cells. In the present study, we show that this region contains a cell-specific DNase-hypersensitive site that represents a potential binding site for a tissue-specific transcription factor. This region contains a consensus HNF-1 site at nucleotide Ϫ55 that is highly conserved between mice and humans. Mutations that disrupt the consensus HNF-1 binding site inhibit promoter activity in transiently transfected renal epithelial cells. Studies using EMSA show that HNF-1␣ and HNF-1␤ bind specifically to the Ϫ55 site of the Ksp-cadherin promoter. Cotransfection experiments show that HNF-1␣ and HNF-1␤ both transactivate the promoter. HNF-1␣ and HNF-1␤ are very likely to activate the promoter directly rather than indirectly, because two independent mutations of the consensus HNF-1 site that prevent HNF-1 binding also prevent transactivation. Expression of a dominant gain-of-function mutant of HNF-1␤ stimulates Kspcadherin promoter activity, whereas expression of a dominant-negative mutant inhibits promoter activity. Taken together, these results demonstrate that HNF-1␣ and HNF-1␤ can directly bind to the Kspcadherin gene promoter and regulate its activity. To our knowledge, Ksp-cadherin is the first kidney-specific promoter that has been shown to be regulated by HNF-1␤.
Recent studies suggest that HNF-1␣ plays an important role in gene regulation in the renal proximal tubule. The promoter of the cytosolic phosphoenolpyruvate carboxykinase (PEPCK) gene contains an HNF-1 binding site that is essential for its expression in renal proximal tubules in transgenic mice (23) . Studies in cultured cells have shown that HNF-1␣ can also regulate the promoters of the facilitative glucose transporter (GLUT2) and dipeptidyl peptidase IV, genes that are expressed in renal proximal tubules and in other tissues (8, 14) . Knockout mice that lack HNF-1␣ develop renal Fanconi syndrome with glucosuria (24) , and humans with heterozygous mutations of HNF-1␣ have a diminished renal threshold for glucose (21) . The impairment in urinary glucose reabsorption in HNF-1␣ mutant mice is because of decreased expression of SGLT2, which encodes an Na ϩ /glucose cotransporter that is expressed in renal proximal tubules and the intestine (25) . These results suggest that HNF-1␣ regulates tissue-specific gene expression in the proximal tubule. Although HNF-1␣ can bind to the Kspcadherin promoter, the expression of Ksp-cadherin transcripts is not altered in HNF-1␣ mutant mice, suggesting that HNF-1␣ is not essential for Ksp-cadherin gene expression. It is possible that expression of HNF-1␤ compensates for the absence of HNF-1␣. The majority of genes with cis-acting elements that bind to HNF-1␣, including SGLT1, GLUT2, and PEPCK, are not affected by the lack of HNF-1␣, probably because of the abundant expression of HNF-1␤ in the kidney.
HNF-1␤ can also bind to the Ksp-cadherin promoter and stimulate its activity. HNF-1␤ has previously been shown to regulate the cAMP-dependent transcription of the urokinase-type plasminogen activator gene in LLC-PK 1 renal epithelial cells (18) . During kidney development, the expression of HNF-1␤ coincides with renal tubulogenesis (9, 17, 22) . Like Ksp-cadherin, HNF-1␤ is expressed in all segments of the nephron and in renal collecting tubules, mesonephric tubules, mesonephric duct, ureteric bud, and Mü llerian duct. Ksp-cadherin is expressed in mIMCD-3 cells that endogenously express HNF-1␤ but do not express HNF-1␣. Taken together with the observation that mutations of HNF-1␤ affect Ksp-cadherin promoter activity in transfected cells, these results suggest that HNF-1␤ may be the principal member of the HNF-1 family that regulates the Ksp-cadherin promoter in vivo. However, the function of HNF-1␤ in the kidney remains unclear because HNF-1␤ mutant embryos do not survive past embryonic day 7.5, which is before the period of kidney organogenesis and Ksp-cadherin expression (3, 10) . Studies using conditional gene targeting will be needed to determine whether HNF-1␤ is required for Kspcadherin gene expression in the kidney and GU tract.
Mutations of the human HNF-1␤ gene (TCF2) are responsible for the autosomal dominant disorder maturity-onset diabetes mellitus of the young, type 5 (MODY5). In addition to impaired insulin secretion, some patients with MODY5 develop renal cysts and abnormalities of the female genital tract, including rudimentary uterus and vaginal aplasia (4, 36) . Mutations of HNF-1␤ that involve the homeodomain and/or POU domain interfere with DNA binding and produce loss-of-function or dominant-negative effects (32) . In the present study, a mouse HNF-1␤ mutant (A263fsinsGG) lacking the third helix of the homeodomain inhibited the activation of the Ksp-cadherin promoter produced by wild-type HNF-1␤, consistent with a dominant-negative mutation. In contrast, the P328L329fsdelCCTCT mutation of human HNF-1␤ produces a dominant gain-offunction mutant. This mutation consists of a deletion of a CCTCT pentanucleotide at codon 328 that is predicted to encode a truncated protein containing an intact homeodomain and POU domain in which 230 amino acids have been deleted from the COOH terminus and replaced with 29 amino acids from the frame-shifted reading frame (5) . Previous studies have shown that expression of the P328L329fsdelCCTCT mutant in HeLa cells produces greater activation of a synthetic promoter containing four HNF-1 binding sites than expression of wild-type HNF-1␤ (35) .
In the present study, we extend these results by showing that a mouse HNF-1␤ mutant lacking 236 amino acids at the COOH terminus functions as a dominant activator of the Ksp-cadherin gene promoter. Deletion of the COOH-terminal domain by itself is sufficient to produce constitutive activation, indicating that the 29 amino acids that are introduced by the frame-shifted open reading frame are not required.
The mechanism by which deletion of the COOH-terminal domain of HNF-1␤ produces constitutive transcriptional activation is not known. Mammalian one-hybrid assays unexpectedly showed that the deleted region of the COOH terminus did not contain a transrepression domain (data not shown). Rather, a GAL4 fusion protein containing the COOH terminus strongly stimulated the activity of a GAL4-responsive promoter, demonstrating that the COOH terminus of mouse HNF-1␤, like HNF-1␣, contains a transactivation domain. The reason deletion of the transactivation domain produces a stronger activator is not known but is likely to involve complex interactions of the COOH terminus with the rest of the HNF-1␤ protein.
Humans who are heterozygous for mutations of the HNF-1␤ gene (TCF2) exhibit renal cystic diseases, including cystic dysplasia and the hypoplastic form of glomerulocystic disease. However, the target genes that are responsible for these phenotypes are not known. The observation that HNF-1␤ regulates the activity of the Ksp-cadherin promoter raises the possibility that dysregulated expression of Ksp-cadherin, a putative cell adhesion molecule of urogenital epithelia, may contribute to developmental abnormalities of the kidney and GU tract in humans with HNF-1␤ mutations. Further studies will be required to determine whether the expression of Ksp-cadherin is affected in humans with MODY5 and kidney cysts.
